U.S. Stock Market Midday Update: Nektar Therapeutics up 8.95%

U.S. Stock Market Midday Update

Nektar Therapeutics rose 8.95%, with increased trading volume. Based on recent important news:

1. On July 9, B. Riley Securities raised the target price for Nektar Therapeutics from $60 to $85, driving the stock price up by 8.95%.

2. On July 8, Innovent Biologics received an upgrade from Daiwa to a target price of HKD 95, indicating a positive trend in the biotechnology industry.

3. On July 8, Zhuoran Co., Ltd. sold subsidiary equity to optimize its asset structure and enhance company competitiveness.

Stocks with High Trading Volume in the Industry

Verona Pharma rose 0.12%, with a trading volume of 1.315 billion. Based on recent important news:

1. On July 9, Merck announced the acquisition of Verona for approximately $10 billion, which caused the stock price to surge over 20% in pre-market trading.

2. On July 9, Verona's Ohtuvayre drug received FDA approval for COPD treatment, boosting market confidence.

3. On July 9, analysts set a target price of $117.92 for Verona, indicating a potential upside of about 30%.

Eli Lilly rose 1.03%, with increased trading volume. Based on recent important news:

1. On July 9, Eli Lilly's Alzheimer's drug Kisunla received FDA approval for updated labeling, with a new dosing regimen reducing the incidence of adverse events by 41%, driving the stock price up.

2. On July 8, Eli Lilly's diversified product line showed a 100% fat loss rate in clinical trials for Bimagrumab, enhancing market confidence.

3. On July 10, Morgan Stanley raised Eli Lilly's target stock price to $113.5, maintaining an overweight rating.

Merck rose 1.09%, with increased trading volume. Based on recent important news:

1. On July 9, Merck announced the acquisition of Verona Pharma for approximately $10 billion, aimed at strengthening its respiratory treatment business. This news pushed the stock price up by 1.09%.

2. On July 9, Verona Pharma's Ohtuvayre drug received FDA approval last year, with projected annual revenue reaching $2.6 billion by 2030, enhancing Merck's product line.

3. On July 9, analysts expect Ohtuvayre's annual sales to exceed $3 billion, with Merck's diversification strategy gaining market recognition.

Stocks with High Market Capitalization in the Industry

Johnson & Johnson rose 0.89%, with a market capitalization of $379.4 billion. Based on recent important news:

1. On July 9, the U.S. Federal Circuit Court of Appeals supported Johnson & Johnson in winning a patent dispute with Viatris and Teva Pharmaceuticals, blocking the launch of generic drugs, which drove the stock price up.

2. On July 10, Morgan Stanley raised Johnson & Johnson's target price to $171, enhancing market confidence On July 9th, Johnson & Johnson raised its revenue forecast for 2025, expecting a growth of 3%, boosting investor sentiment